Optometrists fitting pediatric patients with myopia control lenses will soon have an on-label indication for the approach, with the recent FDA approval of CooperVision’s MiSight 1 day contact lens. The approval comes after three-year study data showed the lenses slow myopia progression by 59% as measured by mean cycloplegic spherical equivalent and 52% when measured by mean axial elongation of the eye. 

​The omafilcon A lens is designed for children ages eight to 12 who have a myopia prescription from -0.25D to -6.00D. According to CooperVision, the lens’s design results in clear distance, intermediate and near vision with peripheral treatment zones that create myopic retinal defocus shown to control the rate of myopia progression.

​A daily disposable option is ideal for this patient population, CooperVision says, as it removes any worry about cleaning regimens and gives parents peace of mind if they lose or damage a lens.

​MiSight 1 day will launch in the United States as part of CooperVision’s myopia management initiative beginning in March 2020, according to a company release.